Quest Diagnostics finalizes acquisition of Select PathAI Diagnostics laboratory assets from PathAI

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of the company PathAI diagnostics With AI Pathwith the goal of accelerating the adoption of artificial intelligence and digital pathology to improve the diagnosis of cancer and other diseases.

PathAI remains an independent company focused on developing artificial intelligence and digital pathology solutions for biopharmaceutical companies and pathology laboratories. The transaction will support PathAI’s strategy of scaling investments in artificial intelligence technology and developing its software and algorithms business.

Due to the acquisition of the state-of-the-art, digitized PathAI Diagnostics laboratory in Memphis has been renamed AmeriPath and will operate as a national research, development and solutions center for artificial intelligence and digital technology, supporting Quest’s specialist pathology businesses, AmeriPath and Dermpath Diagnostics. PathAI will continue to maintain a separate research laboratory at the same facility in Memphis, Tennessee to support its biopharmaceutical customers.

Additionally, PathAI and Quest have entered into separate agreements to further accelerate the adoption of AI and digital pathology based on their respective strengths and scale. Specifically, Quest will license PathAI’s AISight™ digital pathology image management system to support Quest pathology laboratories and customer facilities in United States. Quest is also a preferred laboratory services partner for PathAI’s biopharmaceutical customers. Additionally, PathAI and Quest may also collaborate on the development of artificial intelligence algorithms with potential research and clinical applications.

Quest has a long history of strategically implementing artificial intelligence and automation. The company has implemented artificial intelligence, digital and automation technologies in several laboratory and business areas, from microbiology and cytogenetics to sample processing and customer service, improving quality, efficiency and the customer and employee experience.

About PathAI
PathAI aims to improve patient outcomes with a groundbreaking AI-powered pathology platform. Our solutions provide invaluable information to biopharmaceutical companies, researchers and pathology laboratories, ultimately enabling precise pathology and the vision for more effective diagnosis and treatment. For more information, visit www.pathai.com.

About Quest diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, life after life. We provide diagnostic insights based on our laboratory test results to enable people, physicians and organizations to take action to improve health outcomes. Sourced from one of the world’s largest databases of unidentified clinical laboratory results, Quest’s diagnostic insights uncover new opportunities to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves one in three American adults and half of U.S. physicians and hospitals each year United Statesand our nearly 50,000 employees understand that in the right hands and in the right context, our diagnostic insights can inspire action that changes lives and creates a healthier world. www.QuestDiagnostics.com.